Prolonged Hypercoagulability Occurs Following Pelvic and Acetabular Fractures, as Defined by Serial Thrombelastography

Ashley Clarke BSc, Dr. Prism Schneider MD, PhD Department of Surgery, Division of Orthopaedic Trauma



Background

- Major orthopaedic fractures increase risk for venous thromboembolism (VTE)
- Pelvic and acetabular fractures have the highest incidence of VTE (12%), despite prophylaxis
- No specific prophylaxis recommendations, duration of hypercoagulability is unknown



Image 1. Pelvic Fracture X-Ray

- Thrombelastography (TEG) is a whole-blood, point-of-care test evaluating clotting following trauma
- Maximal amplitude (MA) is an output from TEG analysis which can be used to quantify hypercoagulability

Primary Objective: To use serial TEG analysis to quantify the duration of hypercoagulability following pelvic and acetabular fractures

Methods

- Prospective cohort study of adult patients admitted to Foothills Medical Centre (FMC) with surgically treatable pelvic or acetabular fractures
- Exclusion criteria: Current therapeutic levels of anticoagulation, bleeding disorders, burns >20% body surface, active malignancy, currently or expectant pregnancy within 3-months
- TEG analysis timepoints outlined in Table 1:

Table 1. Serial blood draw schedule for TEG analysis

Admission	Post-Operative Day	2-, 4-, 6-week and
	(POD) 1, 3, 5, and 7	3-month follow-up

- Post-operative timepoints captured up to POD7 or discharge, whichever is sooner
- All patients received standardized prophylaxis for 28 days post-operatively

Results

Table 2. Patient Demographics and Baseline Characteristics

Characteristic	No. (%) of Patients*	
Total Patients	17	
Median Age	54 (IQR [47, 61])	
Female	3 (18)	
Pelvic Fractures	9 (53)	
Smoking Status		
Never Smoked	11 (65)	
Past Smoker	3 (18)	
Current Smoker	3 (18)	
Comorbidities	10 (59)	

IQR = Interquartile range
* except where otherwise noted

- 3 VTE events (all acetabular fractures, all males)
 - o VTE 1 POD1
 - VTE 2 POD5
 - VTE 3 4-week
- Highest average MA values (74.0 ± 2.0) occurred on POD7
- 62.5% remained hypercoagulable at 4-weeks following surgery, when prophylaxis is stopped
- > 30% remained hypercoagulable at 6-weeks following surgery
- Almost ¼ were still hypercoagulable at
 3-months following surgery
- Significant difference in age between patients diagnosed with VTE (73.3 ± 12.0 years) and those without (46.5 ± 17.0 years)




Figure 1. Mean maximal amplitude (MA) values on admission and over the study period.

Table 3. Hypercoagulability Summary by Timepoints

Timepoint	Number Hypercoagulable*	MA Value (Avg ± SD)
Admission	3/17 (18)	60.6 ± 5.3
POD 1	7/17 (41)	63.4 ± 3.5
POD 3	13/16 (81)	68.7 ± 3.2
POD 5	12/12 (100)	71.4 ± 2.9
POD 7	6/6 (100)	74.0 ± 2.0
2-week follow up	9/9 (100)	71.8 ± 2.8
4-week follow up	5/8 (63)	66.9 ± 6.1
6-week follow up	4/12 (33)	63.3 ± 5.7
3-month follow up	3/13 (23)	60.5 ± 6.6

* % based on patient availability by timepoint

Discussion

- A substantial number of patients were still hypercoagulable at, and after, the time of prophylaxis discontinuation (4 weeks post-op)
- Prolonged hypercoagulability demonstrated by serial TEG analysis
- Low rate of loss to follow-up
- Limitation of a small sample size

Significance

Based on this evidence, a larger future study could be performed leading to clinical recommendations regarding prophylaxis duration, in this high-risk population.

I would like to acknowledge the Foothills Orthopaedic Trauma Services and Research Team for their support of my Master's Thesis.

Contact: anclarke@ucalgary.ca

